Leo Pharma's US sales organization waited 8 months on approval: "It has had an economic impact"
![While Becki Morison, executive vice president responsible for Global Therapeutic & Value Strategy at Leo Pharma, is disappointed over the 8-month delay of tralokinumab, the wait has also had some benefits | Photo: Leo Pharma/PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13588594.ece/ALTERNATES/schema-16_9/doc7iypcbxb4vkgeowocdm.jpg)
When the US Food and Drug Administration (FDA) approved of Leo Pharma's drug, tralokinumab, as a treatment for atopic dermatitis, the Danish firm's entire US-based sales organization was ready to push the launch button.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.